TWiV 1122: Clinical update with Dr. Daniel Griffin
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In his weekly clinical update, Dr. Griffin discusses expanded use of the RSV vaccine by GSK, how the youngest member of the MicrobeTV family was hospitalized with RSV, why we are seeing more RSV infections than before the pandemic and how administration of monoclonal antibody therapy does not prevent infection but disease, before reviewing the weekly US COVID update, how SARS-CoV-2 affects neurodevelopment of the fetus and probability of preeclampsia, if giving Paxlovid prevents long COVID, and FDA recommends switching from the XBB.1.5 variant to JN.1 for fall COVID-19 vaccine formulations.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Young "Immune" co-host with RSV (YouTube)
- RSV on Immune (MicrobeTV)
- More children hospitalized with RSV after pandemic than before (Pediatrics)
- France supports Nirsevimab for RSV (Influenza and other respiratory viruses)
- Protects against disease not infection Nirsevimab (CIDRAP)
- TWiV tells it likes it is: protects against disease NOT infection (TWiV 695)
- RSV vaccine access expanded 50-59 (CIDRAP)
- GSK RSV vaccine expanded use for high risk 50-year olds (GSK)
- COVID-19 deaths
- COVID-19 national trend
- Neurodevelopmental delay in children whose mothers exposed to SARS-CoV-2 (Scientific Reports)
- Preeclampsia associated with SARS-CoV-2 infection (Journal of Maternal-Fetal & Neonatal Medicine)
- Effectiveness of nirmatelvir/ritonavir in children and adolescents (Nat Comm)
- JN.1 for fall COVID-19 boosters (FDA)
- COVID-19 vaccine booster switch (CIDRAP)
- EUA for pemgarda (FDA)
- Infusion centers near you! (pemgarda.com)
- CDC quarantine guidelines (CDC)
- Early phase of SARS-CoV-2 infection (COVID.gov)
- NIH COVID-19 treatment guidelines (NIH)
- Infectious Disease Society guidelines for treatment and management (IDSociety)
- Drug interaction checker (University of Liverpool)
- Molnupiravir safety and efficiacy (JMV)
- Convalescent plasma recommendations for immunocompromised (ID Society)
- Updated respiratory virus guidelines (CDC)
- What to do when your healthcare provider is infected with SARS-CoV-2 (CDC)
- Managing healthcare staff shortages (CDC)
- Steroids, dexamethasone at the right time (OFID)
- Anticoagulation guidelines (hematology.org)
- Long COVID evidence based review TWiV shout out (TWiV 1088)
- Nirmatrelvir-ritonavir prevents long COVID-19? (JAMA Medicine)
- Contribute to our Floating Doctors fundraiser
- Letters read on TWiV 1122
- Dr. Griffin's COVID treatment summary (pdf)
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to [email protected]